by
Gus Iversen, Editor in Chief | February 27, 2026
Labcorp plans to deploy PathAI’s FDA-cleared AISight Dx digital pathology platform across its U.S. network of anatomic pathology laboratories and affiliated hospital sites, expanding a collaboration that began in 2019.
The Burlington, North Carolina-based laboratory services company said the cloud-based platform will support fully digital workflows, allowing pathologists to review, manage and annotate slides electronically. AISight Dx is cleared by the FDA for primary diagnosis in the United States and carries CE-IVD marking for use in parts of Europe.
According to Labcorp, the system will be implemented across its anatomic pathology operations to enable digital case management, slide review and collaboration. The platform also includes artificial intelligence-based image analysis tools and secure data storage designed to integrate with existing laboratory systems.
Ad Statistics
Times Displayed: 4969
Times Visited: 14 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
"Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," said Dr. Marcia Eisenberg, chief scientific officer at Labcorp. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care — delivering faster, more consistent results for patients and providers."
Labcorp said it will also incorporate digital pathology workflows into its precision medicine offerings.
The Boston-based PathAI develops artificial intelligence tools for pathology and diagnostics. "Labcorp's leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI," said Dr. Andy Beck, cofounder and CEO of PathAI. "The deployment of AISight Dx across Labcorp's network brings high-quality, efficient digital pathology to a national scale."
Labcorp first invested in PathAI in 2019. The companies have since collaborated on AI-driven clinical trial support and the validation of AI-based pathology applications.
Labcorp employs about 71,000 people and operates in approximately 100 countries, providing diagnostic testing and drug development services.
